Form 8-K

8-K — Niki BioSolutions, Inc.

Accession: 0001213900-26-092661

Filed: 2026-08-21

Period: 2026-08-21

CIK: 0001734005

SIC: 3829 (MEASURING & CONTROLLING DEVICES, NEC)

Item: Financial Statements and Exhibits

Documents

8-K — ea0302544-8k_nikibio.htm (Primary)

EX-99.1 — UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 AND DECEMBER 31, 2025, AND FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025 (ea030254401ex99-1.htm)

EX-99.2 — OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025 (ea030254401ex99-2.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0302544-8k_nikibio.htm · Sequence: 1

false

0001734005

2026-08-21

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 21, 2026

Niki BioSolutions, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-38764

42-3265309

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

116 Village Boulevard, Suite 200, Princeton, NJ 08540

(Address of Principal Executive Offices, including zip code)

Registrant’s Telephone Number, Including

Area Code: 609-951-2222

Aptorum Group Limited

17 Hanover Square

London W1S 1BN, United Kingdom

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

NIKI

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 9.01 Financial

Statements and Exhibits

As previously disclosed

in its Current Report on Form 8-K filed with the Securities and Exchange Commission on July 20, 2026 (the “Original Form 8-K”),

on that same day (the “Closing Date”), after obtaining the requisite shareholder approval and satisfying the closing conditions,

Niki BioSolutions, Inc. (formerly known as Aptorum Group Limited, a Cayman Islands exempted company

with limited liability (“Aptorum”)) (the “Company”) consummated its previously announced merger (the “Closing”)

pursuant to that certain Agreement and Plan of Merger on July 14, 2025, (the “Merger Agreement”), between Aptorum and DiamiR

Biosciences Corp., a Delaware corporation (“DiamiR”), pursuant to which, among other matters, Aptorum was to form a direct,

wholly owned subsidiary in the state of Delaware (“Merger Sub”).

Immediately prior to

the Closing Date, Aptorum affected a domestication under Section 388 of the General Corporation Law of the State of Delaware (the “DGCL”)

and Section 206 of the Companies Act (as revised) of the Cayman Islands (the “Domestication”), pursuant to which Aptorum transferred

by way of continuation to and became a Delaware corporation. On July 20, 2026, immediately following the Domestication, Merger Sub merged

with and into DiamiR in accordance with the applicable provisions of the DGCL, with DiamiR continuing as the surviving company and a wholly-owned

subsidiary of Aptorum (the “Merger”).

Since the Domestication

resulted in a change from foreign private issuer status and filing requirements to domestic issuer status and filing requirements, we

are furnishing this Form 8-K to provide six-months interim consolidated financial statements ended June 30, 2026, and to incorporate such

consolidated financial statements into the Company’s registration statements referenced below.

This Form 8-K is

hereby incorporated by reference into the registration statements of the Company on Form

S-8 (Registration Number 333-281028) and Form F-3 (Registration Number 333-292793) and into each prospectus

outstanding under the foregoing registration statements, to the extent not superseded by documents or reports subsequently

filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as

amended.

(d) Exhibits

Exhibit No.

Description

99.1

Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2026 and December 31, 2025, and for the Six Months Ended June 30, 2026 and 2025

99.2

Operating and Financial Review and Prospects in Connection with the Unaudited Interim Consolidated Financial Statements for the Six Months Ended June 30, 2026 and 2025

104

Cover Page Interactive Data File, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Dated: August 21, 2026

NIKI BIOSOLUTIONS, INC.

By:

/s/ Ian Huen

Ian Huen

Chief Executive Officer

EX-99.1 — UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 AND DECEMBER 31, 2025, AND FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025

EX-99.1

Filename: ea030254401ex99-1.htm · Sequence: 2

Exhibit 99.1

Financial Statements

Table of Contents

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025

F-2

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the six months ended June 30, 2026 and 2025

F-3

Unaudited Condensed Consolidated Statements of Changes in Equity for the six months ended June 30, 2026 and 2025

F-4

Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025

F-5

Notes to Unaudited Condensed Consolidated Financial Statements

F-6

F-1

NIKI BIOSOLUTIONS, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, 2026 and December 31, 2025

(Stated in U.S. Dollars)

June 30,

2026

December 31,

2025

ASSETS

Current assets:

Cash

$ 1,834,171

$ 3,452,891

Other receivables and prepayments

200,909

139,633

Total current assets

2,035,080

3,592,524

Long-term investments

15,098,846

Total Assets

$ 17,133,926

$ 18,691,370

LIABILITIES AND EQUITY

LIABILITIES

Current liabilities:

Amounts due to related parties

$ 79,180

Accounts payable and accrued expenses

922,818

1,071,715

Operating lease liabilities, current

24,428

Convertible notes to a related party

3,508,500

3,418,500

Total current liabilities

4,510,498

4,593,823

Warrant Liability

142,000

306,000

Total Liabilities

4,652,498

4,899,823

Commitments and contingencies (Note 17)

TEMPORARY EQUITY

Contingently redeemable warrants

47,000

Total temporary equity

47,000

EQUITY

Class A Ordinary Shares ($0.0001 par value, 999,999,600,000 shares authorized, 634,682 shares issued and outstanding as of June 30, 2026 and as of December 31, 2025(1))

Class B Ordinary Shares ($0.0001 par value; 400,000 shares authorized, 179,693 shares issued and outstanding as of June 30, 2026 and December 31, 2025(1))

Additional paid-in capital

97,000,188

Accumulated other comprehensive income

(95,129 )

(92,310 )

Accumulated deficit

(75,118,802 )

(73,792,798 )

Total equity attributable to the shareholders of Niki BioSolutions, Inc.

21,786,337

23,115,160

Non-controlling interests

(9,351,909 )

(9,370,613 )

Total equity

12,434,428

13,744,547

Total Liabilities, Temporary Equity and Equity

$ 17,133,926

$ 18,691,370

(1) All per share amounts and shares outstanding for all periods

have been retroactively restated to reflect the company’s 1 for 10 reverse stock split, which was effective on July 20, 2026.

See accompanying notes to the unaudited condensed

consolidated financial statements.

F-2

NIKI BIOSOLUTIONS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS

OF OPERATIONS AND COMPREHENSIVE LOSS

For the six months ended June 30, 2026 and 2025

(Stated in U.S. Dollars)

For the six months ended

June 30,

2026

2025

Operating expenses

Research and development expenses

$ (383,752 )

$ (19,375 )

General and administrative fees

(427,567 )

(187,422 )

Legal and professional fees

(547,131 )

(418,881 )

Other operating income (expenses)

(56,110 )

222,912

Total operating expenses

(1,414,560 )

(402,766 )

Other income (expenses)

Interest expense, net

(56,740 )

(46,529 )

Change in fair value of warrant liability

164,000

Total other income (expenses), net

107,260

(46,529 )

Net loss

(1,307,300 )

(449,295 )

Less: net loss attributable to non-controlling interests

18,704

(7,515 )

Net loss attributable to Niki BioSolutions, Inc.

$ (1,326,004 )

$ (441,780 )

Net loss per share – basic and diluted

$ (1.6 )

$ (0.6 )

Weighted-average shares outstanding – basic and diluted(1)

814,375

712,679

Net loss

$ (1,307,300 )

$ (449,295 )

Other comprehensive loss

Exchange differences on translation of foreign operations

(2,819 )

(258,322 )

Other comprehensive loss

(2,819 )

(258,322 )

Comprehensive loss

(1,310,119 )

(707,617 )

Less: comprehensive loss (income) attributable to non-controlling interests

18,704

(7,515 )

Comprehensive loss attributable to the shareholders of Niki BioSolutions, Inc.

(1,328,823 )

(700,102 )

(1) All per share amounts and shares outstanding for all periods

have been retroactively restated to reflect the company’s 1 for 10 reverse stock split, which was effective on July 20, 2026.

See accompanying notes to the unaudited condensed

consolidated financial statements.

F-3

NIKI BIOSOLUTIONS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS

OF CHANGES IN EQUITY

For the six months ended June 30, 2026 and 2025

(Stated in U.S. Dollars)

Class A

Ordinary Shares

Class B

Ordinary Shares

Additional

Paid-in

Capital

Accumulated

deficit

Accumulated

other

comprehensive

(loss) income

Non-

controlling

interests

Total

Amount

Balance, January 1, 2026(1)

634,682

$ 62

179,693

$ 18

$ 97,000,188

$ (73,792,798 )

$ (92,310 )

$ (9,370,613 )

$ 13,744,547

Net loss

(1,326,004 )

18,704

(1,307,300 )

Exchange difference on translation of foreign operations

(2,819 )

Balance, June 30, 2026(1)

634,682

$ 62

179,693

$ 18

$ 97,000,188

$ (75,118,802 )

$ (95,129 )

$ (9,351,909 )

$ 12,434,428

Balance, January 1, 2025(1)

381,182

$ 37

179,693

$ 18

$ 93,474,825

$ (72,429,528 )

$ 89,162

$ (9,357,453 )

$ 11,777,061

Placing of Class A Ordinary Shares(1)

153,500

2,699,185

2,699,200

Net loss

(441,780 )

(7,515 )

(449,295 )

Exchange difference on translation of foreign operations

(258,322 )

Balance, June 30, 2025(1)

534,682

$ 52

179,693

$ 18

$ 96,174,010

$ (72,871,308 )

$ (169,160 )

$ (9,364,968 )

$ 13,768,644

(1) All per share amounts and shares outstanding for all periods

have been retroactively restated to reflect the company’s 1 for 10 reverse stock split, which was effective on July 20, 2026.

See accompanying notes to the

unaudited condensed consolidated financial statements.

F-4

NIKI BIOSOLUTIONS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS

OF CASH FLOWS

For the six months ended June 30, 2026 and 2025

(Stated in U.S. Dollars)

For the six months ended

June 30,

2026

2025

Cash flows from operating activities

Net cash used in operating activities

$ (1,553,720 )

$ (816,544 )

Cash flows from investing activities

Net cash used in investing activities

(65,000 )

Cash flows from financing activities

Proceeds from issuance of Class A Ordinary Shares

3,070,000

Payment of offering cost

(370,800 )

Net cash provided by financing activities

2,699,200

Net decrease in cash

(1,618,720 )

1,882,656

Cash - Beginning of period

3,452,891

874,238

Cash - End of period

$ 1,834,171

$ 2,756,894

See accompanying notes to the unaudited condensed

consolidated financial statements.

F-5

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

1. ORGANIZATION

The unaudited condensed consolidated financial

statements include the financial statements of Niki BioSolutions, Inc. (the “Company” or “Niki”) and its subsidiaries

of which the Company is the primary beneficiary (collectively the “Group”).

The Company, formerly known as Aptorum Group Limited

(the “Aptorum”), APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, is a company incorporated on September

13, 2010 under the laws of the Cayman Islands with limited liability, and subsequently domesticated to U.S. on July 20, 2026.

The Company researches and develops life science

and biopharmaceutical products within its wholly-owned subsidiary, Aptorum Therapeutics Limited, formerly known as APTUS Therapeutics

Limited (“Aptorum Therapeutics”) and its indirect subsidiary companies (collectively, “Aptorum Therapeutics Group”).

On July 20, 2026 (the “Closing Date”),

after obtaining the requisite shareholder approval and satisfying the closing conditions, Aptorum consummated its previously announced

merger (the “Closing”) pursuant to that certain Agreement and Plan of Merger on July 14, 2025, (the “Merger Agreement”),

between Aptorum and DiamiR Biosciences Corp., a Delaware corporation, pursuant to which, among other matters, Aptorum was to form a direct,

wholly owned subsidiary in the state of Delaware (“Merger Sub”).

Pursuant to the terms of the Merger Agreement,

immediately prior to the Closing on July 20, 2026, Aptorum affected a domestication under Section 388 of the General Corporation Law of

the State of Delaware (the “DGCL”) and Section 206 of the Companies Act (as revised) of the Cayman Islands (the “Domestication”),

pursuant to which Aptorum transferred by way of continuation to and became a Delaware corporation. On July 20, 2026, immediately following

the Domestication, Merger Sub merged with and into DiamiR in accordance with the applicable provisions of the DGCL, with DiamiR continuing

as the surviving company and a wholly-owned subsidiary of Aptorum (the “Merger”). As part of the Domestication, Aptorum changed

its name to Niki BioSolutions, Inc. and filed Niki’s Certificate of Incorporation with the Delaware Secretary of State, which replaced

Aptorum’s memorandum and articles in effect as of such time. In connection with the Merger, the Company’s common stock, par

value $0.0001 per share (the “Niki Common Stock”), trades on Nasdaq under the symbol “NIKI”. In connection with

the name change, the CUSIP number for the Niki Common Stock is 653942 102.

Following the Domestication, each then issued

and outstanding Class A ordinary share of Aptorum converted automatically, on a one-for-one basis, into a share of Niki’s common

stock, par value $0.0001 per share, and each then issued and outstanding Class B ordinary share of Aptorum converted automatically into

a share of Niki Common Stock and a share of Niki’s non-voting and non-convertible Series A preferred stock (the “Series A

Preferred Stock”). Accordingly, a total of 814,375 shares of Niki Common Stock and 179,693 shares of Series A Preferred Stock, respectively,

were issued to Aptorum’s existing shareholders.

Pursuant to the Merger, each then-outstanding

share of DiamiR’s common stock were converted into a number of shares of Niki Common Stock equal to the Conversion Ratio, which

was the number resulting from dividing (i) 0.4102, which is the quotient of dividing the total number of Aptorum ordinary shares on a

fully diluted basis by the total number of shares of DiamiR common stock on a fully diluted basis, by (ii) three-seventh (3/7). Accordingly,

a total of 1,979,216 shares of Niki Common Stock were issued to current stockholders of DiamiR; no shares of Series A Preferred Stock

was issued to any current DiamiR stockholders.

F-6

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

Concurrently with the execution of the Merger

Agreement, DiamiR and Aptorum Therapeutics Limited, a wholly owned subsidiary of Aptorum (“Aptorum Therapeutics”), entered

into a management services agreement (as amended, the “Management Services Agreement”), which terminated as of the closing

of the transaction contemplated by the Merger Agreement. In addition, concurrently with the execution of the Merger Agreement, DiamiR,

DiamiR, LLC, a wholly owned subsidiary of DiamiR, Aptorum and Aptorum Therapeutics entered into an intellectual property license agreement

(“Licensing Agreement”), pursuant to which DiamiR and DiamiR, LLC shall license on a non-exclusive basis their respective

intellectual properties to Aptorum Therapeutics in exchange for upfront and periodic payments and royalties until the earlier of the closing

of the Merger or July 31, 2026, and therefore it terminated as of the Closing. The parties also entered into a Voting and Support Agreement,

as well as a Stockholder Agreement (collectively with the Management Services Agreement and Licensing Agreement, the “Transaction

Documents”), pursuant to which certain parties agreed to vote in favor of certain corporate actions.

2. GOING CONCERN

The Group reported a net loss of $1,307,300, negative

working capital of $2,475,418 and net operating cash outflow of $1,553,720 for the six months ended June 30, 2026. In addition, the Group

had an accumulated deficit of $75,118,802 as of June 30, 2026. The Group’s operating results for future periods are subject to numerous

uncertainties and it is uncertain if the Group will be able to reduce or eliminate its net losses for the foreseeable future. Following the completion of the merger with DiamiR in July 2026, management’s going concern assessment also considered DiamiR’s

financial condition and cash flow forecast as part of the Group’s liquidity analysis for the twelve months following the issuance

of these unaudited condensed consolidated financial statements. DiamiR has a limited operating history, has incurred recurring net losses

and negative operating cash flows, and its standalone financial statements indicate that its existing capital is not expected to be sufficient

to fund its operations for the next twelve months without additional financing. If management

is not able to generate significant revenues from its product candidates currently in development, the Group may not be able to achieve

profitability. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support

the Group’s cost structure. In connection with the Company’s assessment of going concern considerations in accordance with

Financial Accounting Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties

about an Entity’s Ability to Continue as a Going Concern,” management has determined that these conditions raise substantial

doubt about the Group’s ability to continue as a going concern within one year after the date that these financial statements are

issued.

If the Group is unable to generate sufficient

funds to finance the working capital requirements of the Group within the normal operating cycle of a twelve-month period from the date

of these consolidated financial statements are issued, the Group may have to consider supplementing its available sources of funds through

the following sources:

● other available sources of financing from banks and other

financial institutions or private lender; and

● equity financing.

The Group can make no assurances that required

financings will be available for the amounts needed, or on terms commercially acceptable to the Group, if at all. If one or all of these

events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there would likely be

a material adverse effect on the Group and would materially adversely affect its ability to continue as a going concern.

The accompanying unaudited condensed consolidated

financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the unaudited

condensed consolidated financial statements have been prepared on a basis that assumes the Group will continue as a going concern and

which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

F-7

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of presentation and consolidation

The unaudited condensed consolidated financial

statements of the Group are presented on the accrual basis of accounting in accordance with accounting principles generally accepted in

the United States of America (“U.S. GAAP”) for interim financial information, and with the rules and regulations of the United

States Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and footnotes

required by U.S. GAAP for complete financial statements. Unaudited interim results are not necessarily indicative of the results for the

full fiscal year. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with audited consolidated

financial statements and accompanying notes in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025.

The unaudited condensed consolidated financial statements include the accounts of the Company, its direct and indirect wholly and majority

owned subsidiaries. In accordance with the provisions of Accounting Standards Codification (“ASC”) 810, Consolidation, the

Group also consolidate any variable interest entity (“VIE”) of which the Group is the primary beneficiary. The Group do not

consolidate a VIE in which the Group has a majority ownership interest when the Group is not considered the primary beneficiary. The Group

has determined that the Group is not the primary beneficiary of one of the VIE (see Note 11, Variable Interest Entity). The Company evaluates

its relationships with the VIE on an ongoing basis to determine whether it becomes the primary beneficiary. All material intercompany

balances and transactions have been eliminated in preparation of the consolidated financial statements.

Use of estimates

The preparation of the unaudited condensed consolidated

financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts

of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements as

well as income and expenses during the reporting period. Actual results could differ from those estimates. There is no significant accounting

estimate.

Impairment of long-lived assets

The Group prepares a qualitative assessment, and

if necessary, a quantitative assessment, in determining whether long-lived assets may be impaired. The factors considered in the qualitative

assessment include macroeconomic conditions, industry and market conditions and overall financial performance of the Group, among other

factors. Under a quantitative assessment, the Group compares the carrying value of the long-lived assets to the estimated undiscounted

future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted

cash flow is less than the carrying amount of the assets, the Group would recognize an impairment loss, which is the excess of carrying

amount over the fair value of the assets, using the expected future discounted cash flows.

Long-term investments

The Group’s long-term investments consist

of equity method investment in common stocks and non-marketable investments in non-redeemable preferred shares of privately-held companies

that are not required to be consolidated under the variable interest or voting models. Long-term investments are classified as non-current

assets on the unaudited condensed consolidated balance sheets as those investments do not have stated contractual maturity dates.

Non-marketable investments

The non-marketable equity securities not accounted

for under the equity method are measured at cost, less any impairment, plus or minus changes resulting from observable price changes in

orderly transactions for identical or similar investments of the same issuer. Adjustments are determined primarily based on a market approach

as of the transaction date. The Group also makes a qualitative assessment of whether the investment is impaired at each reporting date.

If a qualitative assessment indicates that the investment is impaired, the Group has to estimate the investment’s fair value in

accordance with the principles of ASC 820. If the fair value is less than the investment’s carrying value, the Group recognizes

an impairment loss in earnings equal to the difference between the carrying value and fair value.

F-8

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

Equity method investment – Fair value option

The Group elects the fair value option for an

investment that would otherwise be accounted for using the equity method of accounting. Such election is irrevocable and is applied on

an investment by investment basis at initial recognition. The fair value of such investments is based on quoted prices in an active market,

if any, or recent orderly transactions for identical or similar investment of the same issuer. Changes in the fair value of these equity

method investments are recognized in other (expenses) income, net in the unaudited condensed consolidated statement of operations and

comprehensive loss.

Fair value measurement

Fair value is defined as the price that would

be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement

date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the

Group considers the principal or most advantageous market in which it would transact its business, and it considers assumptions that market

participants would use when pricing the asset or liability.

As a basis for considering such assumptions, a

three-tier fair value hierarchy prioritizes the inputs utilized in measuring fair value as follows:

● Level 1 applies to assets or liabilities for which there

are quoted prices in active markets for identical assets or liabilities.

● Level 2 applies to assets or liabilities for which there

are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for

similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume

or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived

principally from, or corroborated by, observable market data.

● Level 3 applies to assets or liabilities for which there

are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The hierarchy requires the Group to maximize the

use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization

within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

Assets and Liabilities Measured at Fair Value

on a Recurring Basis

The following tables represent the fair value

hierarchy of the Group’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2026 and December

31, 2025.

As of June 30, 2026

Fair Value Measurement at the Reporting Date using

Quoted price

in active

markets for

identical assets

Level 1

Significant

other observable

inputs

Level 2

Significant

unobservable

inputs

Level 3

Total

Financial liabilities:

Warrant liabilities

142,000

Total

$ -

$ 142,000

F-9

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

As of December 31, 2025

Fair Value Measurement at the Reporting Date using

Quoted price

in active

markets for

identical assets

Level 1

Significant

other observable

inputs

Level 2

Significant

unobservable

inputs

Level 3

Total

Financial liabilities:

Warrant liabilities

306,000

Total

$ -

$ 306,000

The Group has determined that the carrying value

of the Group’s cash and cash equivalents, other receivables and prepayments, amounts due to related parties, accounts payable and

accrued expenses, convertible notes to a related party approximate fair value due to the short-term nature of these assets and liabilities.

Segment reporting

The Group uses the management approach to determine

operating segment. The management approach considers the internal organization and reporting used by the Group’s chief operating

decision maker (“CODM’’) for making decisions, allocation of resource and assessing performance.

The Group operates and manages its business as

a single operating and reportable segment. The Group’s CODM has been identified as the Chief Executive Officer who reviews the consolidated

net loss when making decisions about allocating resources and assessing performance of the Group. Significant segment expenses are the

same as these presented under the operating costs and expenses in the consolidated statements of operations, and the difference between

net revenue less the significant segment expenses and consolidated net income are the other segment items. The CODM reviews and utilizes

these financial metrics together with non-financial metrics to make operation decisions, such as the determination of the fee rate at

which the Company charges for its services and the allocation of budget between operating costs and expense.

The Group’s long-lived assets are substantially

all located in Hong Kong and substantially all of the Group’s revenues are derived from within Hong Kong. Therefore, no geographical

segments are presented.

Operating leases

At the inception of a contract, the Group determines

if the arrangement is, or contains, a lease. Operating lease liabilities are recognized at lease commencement based on the present value

of lease payments over the lease term. Operating lease right-of-use assets are initially measured at cost, which comprises the initial

amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs

incurred and less any lease incentives received. As the rate implicit in the lease cannot be readily determined, the Group uses incremental

borrowing rate at the lease commencement date in determining the imputed interest and present value of lease payments. The incremental

borrowing rate is determined based on the rate of interest that the Group would have to pay to borrow an amount equal to the lease payments

on a collateralized basis over a similar term in a similar economic environment. The lease term for all of the Group’s leases includes

the non-cancellable period of the lease plus any additional periods covered by either a Group’s option to extend (or not to terminate)

the lease that the Group is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor.

For operating leases, the Group recognizes a single lease cost on a straight-line basis over the remaining lease term.

The Group has elected not to recognize right-of-use

assets or lease liabilities for leases with an initial term of 12 months or less and the Group recognizes lease expense for these leases

on a straight-line basis over the lease terms.

F-10

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

Recently issued accounting standards which

have not yet been adopted

ASU No. 2024-03, Income Statement-Reporting

Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”),

was issued in November 2024, which requires disclosure in the notes to the financial statements, of disaggregated information about

certain costs and expenses that are included in expense line items on the face of the income statement. The requirements of ASU 2024-03

are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after

December 15, 2027 with early adoption permitted. The Group is currently evaluating the impact, if any, that the adoption of this

standard will have on its Consolidated Financial Statements and disclosures.

The Group does not believe other recently issued

but not yet effective accounting standards, if currently adopted, would have a material impact on the consolidated financial statements.

4. LONG-TERM INVESTMENT

The following table of June 30, 2026 and December

31, 2025, the Group’s long-term investment consists of non-marketable investments with carrying value of $15,098,846 and equity

method investment at fair value option with carrying value of $nil.

Non-marketable investments

The Group’s non-marketable investments are

investments in privately held companies without readily determinable fair values. The carrying value of the non-marketable investments

are adjusted based on price changes from observable transactions of identical or similar securities of the same issuer (referred to as

the measurement alternative) or for impairment if the carrying amount of the non-marketable investments may not be fully recoverable.

Any changes in carrying value are recorded within other (expenses) income, net in the unaudited condensed consolidated statements of operations

and comprehensive loss.

The following table summarizes the total carrying

value of the non-marketable investments held as of June 30, 2026 and December 31, 2025 including cumulative unrealized upward and

downward adjustments and impairment made to the initial cost basis of the investments:

June 30, 2026

December 31, 2025

Cost

basis

Upward

adjustments

Impairment

Carrying

value

Cost

basis

Upward

adjustments

Impairment

Carrying

value

Investment A (1)

$ 2,558,886

$ 12,539,960

$ -

$ 15,098,846

$ 2,558,886

$ 12,539,960

$ -

$ 15,098,846

Investment B (2)

1,000,000

(1,000,000 )

1,000,000

(1,000,000 )

Investment C

520,821

(520,821 )

520,821

(520,821 )

$ 4,079,707

$ 12,539,960

$ (1,520,821 )

$ 15,098,846

$ 4,079,707

$ 12,539,960

$ (1,520,821 )

$ 15,098,846

There is no upward or downwards adjustments and

impairment recorded in other income (expenses), net, and included as adjustments to the carrying value of non-marketable investments held

during the six months ended June 30, 2026 and 2025 based on the observable price in an orderly transaction for the same or similar

security of the same issuers.

(1) The Group holds 622,600 Series B preferred stock of Alzheon,

Inc. (“Alzheon”) with initial cost of $2.6 million with unit price of $4.11, which represents 240,773 common stock converted

as a conversion rate of $10.63. Pursuant to ASC 321-10-35-2, as the investment in Alzheon lacks readily determinable fair values, the

Group elects to account for this investment using the measurement alternative. The Group reviews Alzehon’s available financial

information and adjusts the carrying value of its investment based on preferred stock issuances reflected therein, which were deemed

as observable price changes in orderly transactions for the identical or similar investment of the same issuer.

F-11

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

During the year ended December 31, 2022,

Alzheon issued its Series D preferred stock at $36.00 per share for aggregate gross proceeds of $50 million. During the year ended December

31, 2023, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds of $45 million. During

the year ended December 31, 2024, Alzheon issued its Series E convertible preferred stock at a per share price of $62.71 for gross proceeds

of $78 million. During the year ended December 31, 2025, Alzheon issued its Series E convertible preferred stock at a per share price

of $62.71 for gross proceeds of $5 million. Aside from the conversion price of the conversion rights being different, the other key terms,

including liquidation right, conversion right, voting power, dividend right and redemption right are aligned for Series B, Series D and

Series E convertible preferred stocks. The Group determines the Series D and Series E convertible preferred stocks financings are orderly

transactions between market participants for the identical or a similar investment of the same issuer and recorded as an upward in the

carrying value of the security measured in accordance with paragraph 321-10-35-2 to reflect the current fair value of the security as

of the date that the observable transaction for the similar security took place.

The Group made an upward adjustment

of $6,108,872, from $2,558,886 to $8,667,758, based on Series D convertible preferred stock financing for the year ended December 31,

2022, and made an upward adjustment of $6,431,088, from $8,667,758 to $15,098,846, based on Series E convertible preferred stock financing

for the year ended December 31, 2023. No such upward adjustments were made during the six months ended June 30, 2026 and 2025.

The Group conducts a quarterly assessment

to determine whether impairment exists in Alzheon’s equity securities, considering, among other factors, the nature of the securities,

financial condition of Alzheon and expected future cash flows. No impairment indicator was identified, and no impairment was made during

the six months ended June 30, 2026 and 2025. The carrying value of the investment with Alzheon was $15,098,846 as of June 30, 2026 and

December 31, 2025.

As of June 30, 2026 and December 31,

2025, this investment was pledged for a convertible note issued to a related party (Note 14).

(2) The Group holds 3,333,333 Series B preferred stock of Investee

B with initial cost of $1.0 million at a purchase price of $0.30 per unit. There was no observable orderly transactions of identical

or similar securities from the same issuer. The Group monitored the financial statements of the Investee B. The Group recorded $1 million

impairment for this investment in the year ended December 31, 2024 since the Group considered the investees’ ability to continue

as a going concern and the investment is not recoverable. The carrying value of this investment was $nil as of June 30, 2026 and December

31, 2025, respectively.

The Group did not sell or transfer

any non-marketable investments or record any realized gains or losses for the non-marketable investments measured at fair value on a

non-recurring basis during the six months ended June 30, 2026 and 2025.

F-12

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

Equity method investment, fair value option

In December 2021, one of the Group’s subsidiaries,

Libra Sciences Limited (“Libra”, formerly known as Aptorum Pharmaceutical Development Limited), issued Class A and Class B

ordinary shares to various parties in exchange of licenses or cash. Each Class A share of Libra is entitled to 1 vote while each Class

B share of Libra is entitled to 10 votes. Upon the share issuance, the Group was holding 97.27% economic interest and 31.51% voting power

in Libra. The Group lost the controlling interest in Libra because it was transferred to a third party, and therefore deconsolidated Libra.

However, the Group still owns 97.27% economic interest and 31.51% voting power, which is deemed as having significant influence over Libra.

As a result, the Group’s investment in Libra is subject to the equity method of accounting. The Group assessed that the fair value

option can better reflect the true value of Libra. Pursuant to ASC 825 – Financial Instruments (“ASC 825”), the Group

elected to apply the fair value option for its investments in Libra and will remeasure its investments in Libra at fair value every reporting

period. For the year ended December 31, 2023, the Group has determined that the carrying value of the investment is not recoverable and

this condition is determined to be other-than-temporary. Consequently, an impairment for the investment of $77,200 has been recognized

as of June 30, 2026 and December 31, 2025, respectively.

The Company’s involvement with Libra includes

equity ownership as mentioned in above and also amounts due from Libra as disclosed in note 12. The primary risks associated with this

involvement include potential financial losses due to Libra’s operational performance or inability to generate sufficient cash flows.

The Company’s maximum exposure to loss resulting from its involvement with Libra is nil for the six months ended June 30, 2026 and

2025 which was the amount due from Libra.

5. OTHER RECEIVABLES AND PREPAYMENTS

Other receivables and prepayments as of June 30, 2026 and December

31, 2025 consisted of:

June 30,

2026

December 31,

2025

(Unaudited)

Prepaid insurance

$ 4,203

$ 17,490

Prepaid service fee

47,672

44,810

Rental deposits

71,823

Loan receivables

65,000

—

Others

12,211

5,510

$ 200,909

$ 139,633

F-13

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

6. PROPERTY AND EQUIPMENT, NET

Property and equipment as of June 30, 2026 and December 31, 2025 consisted

of:

June 30,

2026

December 31,

2025

(Unaudited)

Computer equipment

$ 69,291

Furniture, fixture, and office and medical equipment

32,435

Leasehold improvements

108,187

Laboratory equipment

4,335,722

Motor vehicle under finance leases

239,093

4,784,728

Less: accumulated depreciation and impairment

4,784,728

Property and equipment, net

$ -

For the six months ended June 30, 2026 and 2025,

no impairment loss was recorded.

7. INTANGIBLE ASSETS, NET

Ther are no amortization expenses for intangible

assets for both the six months ended June 30, 2026 and 2025, respectively.

8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of June 30, 2026 and December

31, 2025 consisted of:

June 30,

2026

December 31,

2025

(Unaudited)

Research and development expenses payable

$ 830,766

$ 830,189

Professional fees payable

30,247

185,247

Others

61,805

56,279

$ 922,818

$ 1,071,715

F-14

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

9. INCOME TAXES

The Company and its subsidiaries file tax returns separately.

Income taxes

Cayman Islands: under the current laws of the

Cayman Islands, the Company and its subsidiaries in the Cayman Islands are not subject to taxes on their income and capital gains.

Hong Kong: in accordance with the relevant tax

laws and regulations of Hong Kong, a company registered in Hong Kong is subject to income taxes within Hong Kong at the applicable tax

rate on taxable income. All the Hong Kong subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate of

16.5%. The subsidiaries of the Group in Hong Kong did not have assessable profits that were derived Hong Kong during the six months ended

June 30, 2026 and 2025. Therefore, no Hong Kong profit tax has been provided for in the periods presented.

United Kingdom: in accordance with the relevant

tax laws and regulations of United Kingdom, a company registered in the United Kingdom is subject to income taxes within the United Kingdom

at the applicable tax rate on taxable income. All the United Kingdom subsidiaries that are not entitled to any tax holiday were subject

to income tax at a rate of 19%. The subsidiary of the Group in the United Kingdom did not have assessable profits that were derived from

the United Kingdom during the six months ended June 30, 2026 and 2025. Therefore, no United Kingdom profit tax has been provided for in

the periods presented.

Singapore: in accordance with the relevant tax

laws and regulations of Singapore, a company registered in the Singapore is subject to income taxes within Singapore at the applicable

tax rate on taxable income. All the Singapore subsidiaries that are not entitled to any tax holiday were subject to income tax at a rate

of 17%. The subsidiary in Singapore did not have assessable profits that were derived from Singapore during the six months ended June

30, 2026 and 2025. Therefore, no Singapore profit tax has been provided for in the periods presented.

United States (Nevada): in accordance with the

relevant tax laws and regulations of the United States, a company registered in the United States is subject to income taxes within the

United States at the applicable tax rate on taxable income. All the United States subsidiaries in Nevada that are not entitled to any

tax holiday were subject to income tax at a rate of 21%. The subsidiary in the United States did not have assessable profits that were

derived from the United States during the six months ended June 30, 2026 and 2025. Therefore, no United States profit tax has been provided

for in the periods presented.

On a semi-annually basis, the Group evaluates

the realizability of deferred tax assets by jurisdiction and assesses the need for a valuation allowance. In assessing the realizability

of deferred tax assets, the Group considers historical profitability, evaluation of scheduled reversals of deferred tax liabilities, projected

future taxable income and tax-planning strategies. Valuation allowances have been provided on deferred tax assets where, based on all

available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized

in future periods. After consideration of all positive and negative evidence, the Group believes that as of June 30, 2026, it is more

likely than not the deferred tax assets will not be realized.

F-15

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

10. RELATED PARTY BALANCES AND TRANSACTIONS

The following is a list of a director and related parties to which

the Group has transactions with:

(a)

Ian Huen, the Chief Executive Officer and Executive Director of the Group since November 2023. He was a Non-executive Director from June 2022 to November 2023. Before June 2022, he was the Chief Executive Officer and Executive Director;

(b)

Aeneas Group Limited, an entity controlled by Ian Huen;

(c)

Jurchen Investment Corporation, the holding company and an entity controlled by Ian Huen;

(d)

Libra Sciences Limited, an entity which was originally a wholly owned subsidiary of Aptorum Therapeutics Limited (“ATL”). Since December 30, 2021, Libra has been turned into a related party to the Group due to the voting power owned by ATL is decreased to below 50% but more than 20%; (Note 11).

Amounts due from related party

Amounts due from related party consisted of the following as of June

30, 2026 and December 31, 2025:

June 30,

2026

December 31,

2025

(Unaudited)

Current

Libra Sciences Limited (Note b)

$ 522,192

Allowance for credit loss

(522,192 )

Total

$ -

F-16

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

Amounts due to related parties

Amounts due to related parties consisted of the following as of June

30, 2026 and December 31, 2025:

June 30,

2026

December 31,

2025

(Unaudited)

Current

Aeneas Group Limited (Note a)

$ 79,180

June 30,

2026

December 31,

2025

(Unaudited)

Convertible notes to a related party - Current

Jurchen Investment Corporation (Note 14)

$ 3,508,500

$ 3,418,500

Related party transactions

Related party transactions consisted of the following for the six months

ended June 30, 2026 and 2025:

For the six months ended

June 30,

2026

2025

(Unaudited)

Interest expenses (Note 14)

- Jurchen Investment Corporation

$ 90,000

Note a: On August 13, 2019, Aptorum Therapeutics

Limited (“ATL”), a wholly owned subsidiary of the Company, entered into financing arrangements with Aeneas Group Limited,

a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing ATL to access up to a total $15 million

in line of credit debt financing. Both line of credits have originally matured on August 12, 2022. ATL and Aeneas Group Limited has mutually

agreed to extend the line of credit arrangement further 3 years to August 12, 2024. The interest on the outstanding principal indebtedness

is at the rate of 8% per annum. ATL may early repay, in whole or in part, the principal indebtedness and all interest accrued at any

time prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. As of

the date of this unaudited condensed consolidated financial statements, the undrawn line of credit facility is $12 million.

F-17

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

Note b: On January 13, 2022, ATL entered a line

of credit facility with Libra Sciences Limited to provide up to a total $1 million line of credit for its daily operation. The line of

credit is originally matured on January 12, 2023, and is extended for additional 3 years. The interest on the outstanding principal indebtedness

is at the rate of 10% per annum. ATL and Libra Science Limited mutually agreed to terminate the line of credit agreement effect as of

March 31, 2023. All existing liabilities arising from the line of credit agreement shall remain enforceable and repayable on demand by

ATL. As of the issuance date of this unaudited condensed consolidated financial statements, $0.5 million is outstanding from Libra Sciences

Limited. For the six months ended June 30, 2026 and year ended December 31, 2025, the Group has assessed that the amounts due from Libra

Science Limited and its subsidiary are potentially unrecoverable. Accordingly, as at period ended 30 June 2025 an allowance for credit

loss amounting to $0.5 million has been recognized.

11. VARIABLE INTEREST ENTITY

The Company consolidates VIEs in which the Group

has a variable interest and is determined to be the primary beneficiary. This determination is based on whether the Group has a variable

interest (or combination of variable interests) that provides the Company with (a) the power to direct the activities that most significantly

impact the VIE’s economic performance and (b) the obligation to absorb losses or right to receive benefits that could be potentially

significant to the VIE. The Group continually reassesses whether it is the primary beneficiary of a VIE throughout the entire period the

Group is involved with the VIE.

On December 30, 2021, three of the Group’s

subsidiaries, Libra Sciences Limited (“Libra”, formerly known as Aptorum Pharmaceutical Development Limited),

Mios Pharmaceuticals Limited (“Mios”) and Scipio Life Sciences Limited (“Scipio”), issued Class A and Class B

ordinary shares to various parties; for each such entity, each Class A ordinary share is entitled to 1 vote and 1 share of economic benefit

of the respective company, while each Class B ordinary share is entitled to 10 votes and 0.001 share of economic benefit of the respective

company. Following such share issuances, the Group lost its majority voting rights in each of these three companies and only holds 48.33%,

48.39% and 48.36% economic interest in Libra, Mios and Scipio, respectively. However, the Company still holds a majority of each of these

three company’s outstanding Class A ordinary shares and therefore will absorb/receive portions of these subsidiaries’ expected

losses or residual returns. In addition, none of these three companies have sufficient equity to sustain its own activities, and they

have two classes of ordinary shares which have different rights, benefits and obligations. The Company determined that all these three

companies are variable interest entities (“VIE”). On December 31, 2021, Libra, Mios and Scipio further issued Class A ordinary

shares to a wholly owned subsidiary of the Company in exchange of certain projects licenses. Upon these share issuances, the Company,

through a wholly owned subsidiary, was holding 97.27% economic interest and 31.51% voting power in Libra, 97.93% economic interest and

36.17% voting power in Mios, and 97.93% economic interest and 35.06% voting power in Scipio, respectively.

The Company has considered each of these entity’s

Memorandum and Article of Association and their respective board of directors (the sole director of each of Mios and Scipio is an executive

director of the Group), and determined that The Company has the power to manage and make decisions that affect Mios and Scipio’s

research and development activities, which activities most significantly impact Mios and Scipio’s economic performance. However,

the Company does not have such power over Libra’s research and development activities, which activities most significantly impact

Libra’s economic performance. Accordingly, the Company determined that it is the primary beneficiary of Mios and Scipio, but not

the primary beneficiary of Libra.

F-18

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

In November 2024, the Group acquired 10,000 Class

A Ordinary Shares and 5,850,000 Class B Ordinary Shares of Scipio, achieving control over the entity. As a result of this acquisition,

Scipio is no longer classified as a VIE under the Group and it became a subsidiary under the Group.

In October 2024, Mios was dissolved and

ceased operation and it was deemed disposed by the Group. As at period ended June 30, 2026 and December 31, 2025, the asset

and liability of the consolidated VIE is both zero.

The Group’s maximum exposure to loss from

its involvement with unconsolidated VIE represents the estimated loss that would be incurred if the VIE is liquidated, so that the fair

value of the equity investment in VIE is zero and the amounts due from the VIE have to be fully impaired.

12. LEASE

As of June 30, 2026, the Group has only short-term

operating lease and the non-short-term operating lease for laboratory and clinic was expired in March, 2026. The discount rates reflect

the estimated incremental borrowing rate, which includes an assessment of the credit rating to determine the rate that the Group would

have to pay to borrow, on a collateralized basis for a similar term, an amount equal to the lease payments in a similar economic environment.

For the six months ended

June 30,

2026

2025

(Unaudited)

Lease cost

Operating lease cost

$ -

Short-term lease cost

Total lease cost

$ -

Other information

Cash paid for amounts included in the measurement of lease liabilities

Operating cash flows from operating leases

$ 24,573

$ 39,415

Weighted-average remaining lease term – operating leases

0.7 years

Weighted-average discount rate – operating leases

8.0 %

During the six months ended June 30, 2026 and

2025, there was no impairment recorded on right-of-use assets, respectively, on right-of-use assets because it has been fully impaired

during 2024 as the Group considered that the carrying amount of a right-of-use asset related to leases of laboratory and clinic may not

be recoverable.

F-19

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

13. ORDINARY SHARES

On January 2, 2025, the Company entered into a

certain securities purchase agreement (the “Securities Purchase Agreement”) with certain non-affiliated institutional investors

(the “Purchasers”) pursuant to which the Company sold 153,500 Class A ordinary shares of the Company (the “Shares”),

par value $0.0001 per share (the “Ordinary Shares”) at a per share price of $20.0 in a registered direct offering, for gross

proceeds of $3,070,000 (the “Offering”). and the net proceeds after deducting the related expense is $2,699,200 The Securities

Purchase Agreement was fully executed on January 3, 2025.

On October 14, 2025, the Company closed an offering,

issuing 100,000 Class A ordinary shares and warrants to purchase 200,000 restricted warrants (the “Investor Warrants”), for

aggregate gross proceeds of $2,000,000 (the “October 2025 Offering”). Cash issuance costs are $284,001 and the net proceeds

from the October 2025 Offering were approximately $1,716,000.

Of the $2,000,000 gross proceeds, $996,000 was

allocated to the liability-classified Investor Warrants at their fair value, with the residual $1,004,000 allocated to the equity-classified

Class A ordinary shares.

In connection with the October 2025 Offering,

the Company issued warrants to purchase 6,018 Class A ordinary shares to the placement agent’s designees (the “Placement Agent

Warrants”) at an exercise price of $25.0 per share. The Placement Agent Warrants had a grant-date fair value of $23,606 (see Note

16) which was treated as an issuance cost of the offering.

Cash issuance costs of $284,001 and the Placement

Agent Warrant fair value of $23,606 were allocated between the liability and equity instruments in proportion to the allocation of proceeds

($141,433 and $11,756, respectively, to the warrant liability, expensed as incurred; and $142,568 and $11,850, respectively, to equity,

charged to additional paid-in capital).

Holders of Class A Ordinary Shares and Class B

Ordinary Shares have the same rights except for the following: (i) each Class A Ordinary Share is entitled to one vote while each Class

B Ordinary Share is entitled to ten votes; and (ii) each Class B Ordinary Share is convertible into one Class A Ordinary Share at any

time while Class A Ordinary Shares are not convertible under any circumstances.

On July 20, 2026, the Company effectuated a 10

for 1 share consolidation of its authorized share capital, such that every 10 Class A Ordinary Shares, par value of US$0.00001 per share,

in the authorized share capital of the Company (including issued and unissued share capital) be consolidated into 1 Class A Ordinary Share,

par value of US$0.0001 per share, and that every 10 Class B Ordinary Shares, par value of US$0.00001 per share in the authorized share

capital of Aptorum (including issued and unissued share capital) be consolidated into 1 Class B Ordinary Share, par value of US$0.0001

per share (the “Share Consolidation” or “Reverse Split”). The Reverse Split was approved by the Company’s

shareholders on June 9, 2026 and Company’s board of directors approved implementing the Reverse Split effective as of July 20, 2026.

Accordingly, the Reverse Split was effective and the Class A Ordinary Shares began trading on a split-adjusted basis when the market opened

on July 20, 2026. Immediately prior to the Share Consolidation, Company had 6,346,823 Class A Ordinary Shares outstanding and 1,796,934

Class B Ordinary Shares outstanding. Following the Share Consolidation, there are 634,682 Class A Ordinary Shares outstanding and 179,693

Class B Ordinary Shares outstanding (these numbers are based on the current number of shares outstanding and are subject to change, in

either direction, once the Reverse Split is effected on an individual basis). As a result of the Reverse Split, the Company’s authorized

share capital was US$100,000,000 divided into 999,999,600 Class A Ordinary Shares with a par value of US$0.0001 each and 400,000 Class

B Ordinary Shares with a par value of US$0.0001 each. All per share amounts and shares outstanding for all periods have been retroactively

restated to reflect the Reverse Split.

14. CONVERTIBLE NOTE

On September 11, 2023, the Group entered into

a securities purchase agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to which the Group

sold a secured convertible note in the aggregate principal amount of $3,000,000 (the “Sep 2023 Notes”). The Sep 2023 Notes

are convertible into the Company’s Class A Ordinary Shares and have a maturity date that is 24 months from the issuance date, although

upon such date the investor has the right to extend the term of the Sep 2023 Note for twelve (12) months or more or such term subject

to mutual consent. On September 11, 2025, the Group entered into an extension agreement with Jurchen Investment Corporation to extend

the Sep 2023 Notes further for 12 months. The Sep 2023 Notes have an interest rate of 6% per annum and a conversion price of $24.2 per

share. The Company has the right to repay the principal amount of the Sep 2023 Notes, but in the case of such prepayment it must be paid

in cash, unless otherwise agreed by both parties. The Sep 2023 Note is secured by a first priority lien and security interest on certain

preferred shares that the Group owns (“Collateral”) (Note 4). Upon the Group’s disposal of all or a portion of the Collateral,

the investor has the right, to request that the Group prepay the then-remaining outstanding balance of the Sep 2023 Note, in part or in

full and the Group can make that payment in cash or in shares.

F-20

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

15. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted

loss per share:

For the six months ended

June 30,

2026

2025

(Unaudited)

Numerator:

Net loss attributable to Niki BioSolutions, Inc.

(1,326,004 )

$ (441,780 )

Denominator:

Basic and diluted weighted average shares outstanding (1)

814,375

712,680

Basic and diluted loss per share

(1.6 )

$ (0.6 )

(1) All per share amounts and shares outstanding for all periods

have been retroactively restated to reflect the company’s 1 for 10 reverse stock split, which was effective on July 20, 2026.

Basic loss per share is computed by dividing net

loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted loss

per share reflects the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or

converted into ordinary shares. Potential dilutive securities are excluded from the calculation of diluted loss per share in loss periods

as their effect would be anti-dilutive. For the six months ended June 30, 2026 and 2025, the total number of share options, warrants and

convertible notes excluded from the calculation of diluted earnings per share due to their anti-dilutive nature, are 139,840.

16. WARRANTS

In connection with the October 2025 Offering (see

Note 14), the Company issued Investor Warrants to purchase 200,000 Class A ordinary shares and Placement Agent Warrants to purchase 6,018

Class A ordinary shares.

The Investor Warrants are exercisable immediately

at an exercise price of $20.0 per share and expire twenty-four months from the effective date of a registration statement registering

for resale the ordinary shares underlying the Investor Warrants. The Investor Warrants were classified as liabilities under ASC 815 due

to certain settlement provisions that preclude equity classification.

The fair value of the Investor Warrants was determined

using a binomial option pricing model with the following inputs:

As of

June 30,

2026

As of

December 31,

2025

Stock price

$ 7.8

$ 10.6

Exercise price

$ 20.0

Expected term

1.43 years

1.93 years

Risk-free rate

4.07 %

3.48 %

Expected volatility

69.61 %

58.10 %

Dividend rate

0.00 %

Dilution factor

Fair value per share

$ 0.71

$ 1.53

F-21

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

Expected volatility was based on the historical

volatility of comparable publicly traded companies. The Company recognized a gain of $163,000 on the change in fair value of the Investor

Warrant liability for the six months ended June 30, 2026, included in “Change in fair value of warrant liability” in the consolidated

statements of operations.

The Placement Agent Warrants are exercisable immediately

upon issuance and expire on the earlier of (i) 24 months from the effective date of a registration statement or (ii) October 10, 2030.

The grant-date fair value of the Placement Agent

Warrants was $23,606, determined using the Black-Scholes option pricing model with the following inputs: stock price of $15.9, exercise

price of $25.0, expected term of 2.5 years, risk-free rate of 3.48%, and expected volatility of 58.8% based on comparable public companies.

The fair value of the Placement Agent Warrants was treated as an issuance cost of the October 2025 Offering (see Note 13).

The Placement Agent Warrants were classified as

temporary equity under ASC 480-10-S99-3A due to certain contingent redemption provisions in the warrant. The contractual redemption amount

of the Placement Agent Warrants on the issuance date was $47,000, computed using the following contractually specified inputs: stock price

of $15.9, exercise price of $25.0, expected volatility of 100%, risk-free rate of 3.48%, and remaining term of 2.5 years. This amount

was reclassified from additional paid-in capital to temporary equity on the issuance date. Since the contingent event is not probable

to occur, no subsequent remeasurement of the temporary equity amount is required.

As of June 30, 2026, the Company had 206,018 warrants

outstanding to purchase Class A ordinary shares with a weighted-average exercise price of $20.1 and a weighted-average remaining contractual

term of approximately 1.43 years.

17. COMMITMENTS AND CONTINGENCIES

Contingent payment obligation

As of June 30, 2026, the Group does not have any

non-cancellable purchase commitments.

The Group has contingency payment obligations

under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or

milestone is met.

Milestone payments are to be made upon achievements

of certain conditions, such as Investigational New Drugs (“IND”) filing or U.S. Food and Drug Administration (“FDA”)

approval, first commercial sale of the licensed products, or other achievements. The aggregate amount of the milestone payments that the

Group is required to pay up to different achievements of conditions and milestones for all the license agreements signed as of June 30,

2026 are as below:

Amount

(unaudited)

Drug molecules: up to the conditions and milestones of

From entering phase 1 to before first commercial sale

920,000

First commercial sale

800,000

Net sales amount more than certain threshold in a year

7,000,000

Subtotal

$ 8,720,000

F-22

NIKI BIOSOLUTIONS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL

STATEMENTS

(Stated in U.S. Dollars)

For the six months ended June 30, 2026 and 2025,

the Group incurred did not incur any milestone payments. For the six months ended June 30, 2026 and 2025, the Group did not incur any

royalties or research and development funding.

Legal proceedings

The Group is party to a lawsuit initially filed

on notice on September 3, 2024, by Karen Cheung (“Plaintiff”) in the Supreme Court of the State of New York, County of New

York (“State Court Action”) (Index No. 654541/2024), which sought relief arising from (i) violations of the federal Racketeer

Influenced and Corrupt Organizations Act (“RICO”), 18 § U.S.C. 1961(c), (ii)conspiracy to violate RICO, 18 U.S.C. §

1961(d), (iii) fraud, (iii) breach of fiduciary duty, (iv) negligent misrepresentation, (v) unjust enrichment, (vi) civil conspiracy and

(vii) violations of the federal Securities Act of 1933, 15 § U.S.C. 77a et. seq. On December 27, 2024, the Group filed a Notice of

Removal in the U.S. District Court for the Southern District of New York (Case No.1:24-cv-09969-VSB-OTW) removing the State Court Action

to federal court. On December 30, 2024, the Group filed a demand for service of the complaint on the Group. Plaintiff filed and served

her Complaint on the Group on February 24, 2025, alleging claims for (i) violations of RICO 18 U.S.C. § 1962(c), (ii) conspiracy

to violate RICO 18 U.S.C. § 1962(d), (iii) fraud; (iv) aiding and abetting breach of fiduciary duty, (v) unjust enrichment, and (vi)

civil conspiracy. Following a motion, Plaintiff was granted leave to amend her Complaint. On May 30, 2025, Plaintiff filed her First Amended Complaint. The parties filed Joint Stipulation and Proposed Order Regarding Briefing

Schedule ("Briefing Schedule") on June 9, 2025. The Court entered the Briefing Schedule on June 9, 2025, wherein the Company's motion

to dismiss was due July 18, 2025, Plaintiff's opposition was due August 18, 2025, and Company's reply in support of its motion to dismiss

was due September 8, 2025. The Company believes that Plaintiff’s claims are without merit and has filed a motion to dismiss the

Complaint on July 18, 2025. Such motion is now fully briefed and is currently pending with the Court. As such, the Company will continue

to vigorously defend against Plaintiff’s claims. The Court entered an order on July 27, 2026, setting a conference to discuss discovery.

At this time, it is too early to estimate the costs and expenses of defending the lawsuit.

From time to time, the Group may be subject to

certain legal proceedings, claims and disputes that arise in the ordinary course of business. Although the outcomes of these legal proceedings

cannot be predicted, the Group does not believe these actions, in the aggregate, will have a material adverse impact on its financial

position, results of income or liquidity.

18. SUBSEQUENT EVENTS

The Group has evaluated subsequent events through

the date of issuance of the unaudited condensed consolidated financial statements. Except for the events disclosed elsewhere in the unaudited

condensed financial statements and the following events with material financial impact on the Group’s unaudited condensed consolidated

financial statement, no other subsequent event is identified that would have required adjustment or disclosure in the unaudited condensed

consolidated financial statements.

On July 20, 2026, the merger between the Group

and DiamiR Biosciences Corp. (“DiamiR”) closed and the Company changed the name from Aptorum Group Limited to Niki BioSolutions,

Inc., as further described in Note 1. The merger is accounted for as a business combination using the acquisition method of accounting

in accordance with ASC 805. The Group was identified as the accounting acquirer and legal acquirer based on an evaluation of the following

facts and circumstances: (i) although after consummation of the merger, the current equity holders of the Group retaining 30% ownership

interest of the combined company, pursuant to the shareholder agreement, Aptorum still has contractual rights which allow it to designate

a majority of the Board of Directors until DiamiR’s voting interest is less than 25% of the combined entity or until the 2027 Annual

Meeting; (ii) pursuant to the shareholder agreement, Aptorum has the power to appoint three of the five Directors, which is a majority

of the Board of Directors; (iii) Aptorum’s CEO remains in place post-merger and continues to lead strategic initiatives, including

business development and financing; (iv) Aptorum is historically larger size than DiamiR; (v) Aptorum initiated the merger and led negotiations

and the merger aligns with Aptorum’s strategic goals and business model.

As of the date of this report, management has

not yet completed a fair value assessment of the identified assets acquired, and liabilities assumed, of DiamiR at the Closing Date. Accordingly,

no estimate is currently made for any goodwill or bargain purchase gain that may be recognized in connection with the merger.

F-23

EX-99.2 — OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025

EX-99.2

Filename: ea030254401ex99-2.htm · Sequence: 3

Exhibit 99.2

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

IN CONNECTION WITH THE UNAUDITED INTERIM CONSOLIDATED

FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025

You should read the following

discussion and analysis of our financial condition and results of operations in conjunction with our unaudited consolidated financial

statements and the related notes included elsewhere in this Report on Form 6-K and with the discussion and analysis of our financial condition

and results of operations contained in our Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the Securities

and Exchange Commission on April 30, 2026 (the “2025 Form 20-F”). This discussion may contain forward-looking statements based

upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these

forward-looking statements as a result of various factors, including those discussed in the 2025 Form 20-F under the section titled “Risk

Factors” and in other parts of the 2025 Form 20-F. Our consolidated financial statements have been prepared in accordance with U.S.

GAAP.

Overview

are a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to

treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The

pipeline of Aptorum is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification

and detection diagnostics technology with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science,

Technology and Research.

Based

on our evaluation of preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing

therapies, potential market size, competition in market, the Company decides how to prioritize its resources among projects. Overall,

our rationale for selecting Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on a

combination of the factors and individual attributes of the Lead Projects themselves.

Our

goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic

areas. Key components of our strategy for achieving this goal include:

● Developing

therapeutic and diagnostic innovations across a wide range of disease/therapeutic areas;

● Selectively

expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical

needs;

● Collaborating

with leading academic institutions and CROs;

● Expanding

our in-house pharmaceutical development center;

● Leveraging

our management’s expertise, experience and commercial networks;

● Obtaining

and leveraging government grants to fund project development.

have devoted a substantial portion of the proceeds from our offerings to our Lead Projects. Our Lead Projects are ALS-4, SACT-1 and PathsDx.

During the second quarter

of 2023, the Company made a decision to streamline its operations by terminating clinic services and suspending non-lead R&D projects.

This measure is aimed at optimizing the allocation of its resources and focusing its efforts on advancing lead projects, which hold the

most promise for commercial success and beneficial impact. This decision aligns with the Company’s commitment to enhance shareholder

value and effectively drive its core objectives forward in the competitive landscape.

The

Company is party to a lawsuit initially filed on notice on September 3, 2024, by Karen Cheung (“Plaintiff”) in the Supreme

Court of the State of New York, County of New York (“State Court Action”) (Index No. 654541/2024), which sought relief arising

from (i) violations of the federal Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 § U.S.C. 1961(c),

(ii)conspiracy to violate RICO, 18 U.S.C. § 1961(d), (iii) fraud, (iii) breach of fiduciary duty, (iv) negligent misrepresentation,

(v) unjust enrichment, (vi) civil conspiracy and (vii) violations of the federal Securities Act of 1933, 15 § U.S.C. 77a et. seq.

On December 27, 2024, the Company filed a Notice of Removal in the U.S. District Court for the Southern District of New York (Case No.1:24-cv-09969-VSB-OTW)

removing the State Court Action to federal court. On December 30, 2024, the Company filed a demand for service of the complaint on the

Company. Plaintiff filed and served her Complaint on the Company on February 24, 2025, alleging claims for (i) violations of RICO 18 U.S.C.

§ 1962(c), (ii) conspiracy to violate RICO 18 U.S.C. § 1962(d), (iii) fraud; (iv) aiding and abetting breach of fiduciary duty,

(v) unjust enrichment, and (vi) civil conspiracy. Following a motion, Plaintiff was granted leave to amend her Complaint. On May 30, 2025, Plaintiff filed her First Amended Complaint. The parties filed Joint Stipulation and Proposed Order Regarding Briefing

Schedule ("Briefing Schedule") on June 9, 2025. The Court entered the Briefing Schedule on June 9, 2025, wherein the Company's motion

to dismiss was due July 18, 2025, Plaintiff's opposition was due August 18, 2025, and Company's reply in support of its motion to dismiss

was due September 8, 2025. The Company believes that Plaintiff’s claims are without merit and has filed a motion to dismiss the

Complaint on July 18, 2025. Such motion is now fully briefed and is currently pending with the Court. As such, the Company will continue

to vigorously defend against Plaintiff’s claims. The Court entered an order on July 27, 2026, setting a conference to discuss discovery.

At this time, it is too early to estimate the costs and expenses of defending the lawsuit.

Merger with DiamiR Biosciences Corp.

On July 20, 2026 (the “Closing Date”), after obtaining the requisite shareholder approval and satisfying the closing conditions,

Aptorum consummated its previously announced merger (the “Closing”) pursuant to that certain Agreement and Plan of Merger

on July 14, 2025, (the “Merger Agreement”), between Aptorum and DiamiR Biosciences Corp., a Delaware corporation, pursuant

to which, among other matters, Aptorum was to form a direct, wholly owned subsidiary in the state of Delaware (“Merger Sub”).

Pursuant

to the terms of the Merger Agreement, immediately prior to the Closing on July 20, 2026, Aptorum affected a domestication under Section

388 of the General Corporation Law of the State of Delaware (the “DGCL”) and Section 206 of the Companies Act (as revised)

of the Cayman Islands (the “Domestication”), pursuant to which Aptorum transferred by way of continuation to and became a

Delaware corporation. On July 20, 2026, immediately following the Domestication, Merger Sub merged with and into DiamiR in accordance

with the applicable provisions of the DGCL, with DiamiR continuing as the surviving company and a wholly-owned subsidiary of Aptorum (the

“Merger”). As part of the Domestication, Aptorum changed its name to Niki BioSolutions, Inc. and filed Niki’s Certificate

of Incorporation with the Delaware Secretary of State, which replaced Aptorum’s memorandum and articles in effect as of such time.

In connection with the Merger, the Company’s common stock, par value $0.0001 per share (the “Niki Common Stock”), trades

on Nasdaq under the symbol “NIKI”. In connection with the name change, the CUSIP number for the Niki Common Stock is 653942

102.

Following the Domestication, each then issued and outstanding Class A ordinary share of Aptorum converted automatically, on a one-for-one

basis, into a share of Niki’s common stock, par value $0.0001 per share, and each then issued and outstanding Class B ordinary share

of Aptorum converted automatically into a share of Niki Common Stock and a share of Niki’s non-voting and non-convertible Series

A preferred stock (the “Series A Preferred Stock”). Accordingly, a total of 814,375 shares of Niki Common Stock and 179,693

shares of Series A Preferred Stock, respectively, were issued to Aptorum’s existing shareholders.

Pursuant to the Merger, each then-outstanding

share of DiamiR’s common stock were converted into a number of shares of Niki Common Stock equal to the Conversion Ratio, which

was the number resulting from dividing (i) 0.4102, which is the quotient of dividing the total number of Aptorum ordinary shares on a

fully diluted basis by the total number of shares of DiamiR common stock on a fully diluted basis, by (ii) three-seventh (3/7). Accordingly,

a total of 1,979,216 shares of Niki Common Stock were issued to current stockholders of DiamiR; no shares of Series A Preferred Stock

was issued to any current DiamiR stockholders.

Concurrently with the execution of the Merger Agreement, DiamiR and Aptorum Therapeutics

Limited, a wholly owned subsidiary of Aptorum (“Aptorum Therapeutics”), entered into a management services agreement (as amended,

the “Management Services Agreement”), which terminated as of the closing of the transaction contemplated by the Merger Agreement.

In addition, concurrently with the execution of the Merger Agreement, DiamiR, DiamiR, LLC, a wholly owned subsidiary of DiamiR, Aptorum

and Aptorum Therapeutics entered into an intellectual property license agreement (“Licensing Agreement”), pursuant to which

DiamiR and DiamiR, LLC shall license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics in exchange

for upfront and periodic payments and royalties until the earlier of the closing of the Merger or July 31, 2026, and therefore it terminated

as of the Closing. The parties also entered into a Voting and Support Agreement, as well as a Stockholder Agreement (collectively with

the Management Services Agreement and Licensing Agreement, the “Transaction Documents”), pursuant to which certain parties

agreed to vote in favor of certain corporate actions.

On July 20, 2026, the merger

between the Group and DiamiR Biosciences Corp. (“DiamiR”) has been closed and the Company has changed the name from Aptorum

Group Limited to Niki BioSolutions, Inc. The merger is accounted for as a business combination using

the acquisition method of accounting in accordance with ASC 805. The Group was identified as the accounting acquirer and legal acquirer

based on an evaluation of the following facts and circumstances: (i) although after consummation of the merger, the current equity holders

of the Group retaining 30% ownership interest of the combined company, pursuant to the shareholder agreement, Aptorum still has contractual

rights which allow it to designate a majority of the Board of Directors until DiamiR’s voting interest is less than 25% of the combined

entity or until the 2027 Annual Meeting; (ii) pursuant to the shareholder agreement, Aptorum has the power to appoint three of the five

Directors, which is a majority of the Board of Directors; (iii) Aptorum’s CEO remains in place post-merger and continues to lead

strategic initiatives, including business development and financing; (iv) Aptorum is historically larger size than DiamiR; (v) Aptorum

initiated the merger and led negotiations and the merger aligns with Aptorum’s strategic goals and business model.

About DiamiR

DiamiR was incorporated in

Delaware on June 16, 2014, and primarily operates through its wholly owned subsidiary, DiamiR, LLC, which was incorporated as a limited

liability company in Delaware on September 17, 2009. DiamiR is a molecular diagnostics company focused on developing and commercializing

minimally invasive tests for early detection and monitoring of neurodegenerative diseases, such as mild cognitive impairment and Alzheimer’s

disease, rare neurodevelopmental diseases, such as Rett syndrome, other brain health disorders, and cancer. The proprietary platform technology

developed at DiamiR and protected by over 50 issued patents is based on quantitative analysis of organ-enriched microRNAs detectable in

blood plasma. In addition to blood-based microRNA panels, as part of its biopharma services DiamiR’s

CLIA/CAP-certified laboratory offers protein and genetic biomarker analyses for screening, patient stratification, disease

and treatment monitoring.

Factors Affecting our

Results of Operations

Research and Development Expenses

We believe our ability to

successfully develop innovative drug candidates will be the primary factor affecting our long-term competitiveness, as well as our future

growth and development. Creating high quality global first-in-class or best-in-class drug candidates requires significant investment of

resources over a prolonged period of time. As a result of this commitment, our pipeline of drug candidates has been steadily advancing.

Our drug candidates are still

in development, and we have incurred and will continue to incur significant research and development costs for pre-clinical studies and

clinical trials. We expect that our research and development expenses may significantly increase in future periods in line with the advancement

and expansion of the development of our drug candidates.

have been able to fund the research and development expenses for our drug candidates through a range of sources, including the proceeds

raised from our public offering and follow-on offerings on Nasdaq, private placement to other investors and line of credit facilities

from shareholders, related parties and banks.

This

diversified approach to funding allows us to not depend on any one method of funding for our research and development activities, thereby

reducing the risk that sufficient financing will be unavailable as we continue to accelerate the development of our drug candidates.

RESULTS OF OPERATION

For the six months ended

June 30, 2026 and 2025

The following table summarizes

our results of operations for the six months ended June 30, 2026 and 2025.

For the six months ended

June 30,

2026

2025

(Unaudited)

Operating expenses

Research and development expenses

(383,752 )

(19,375 )

General and administrative fees

(427,567 )

(187,422 )

Legal and professional fees

(547,131 )

(418,881 )

Other operating (expenses) income

(56,110 )

222,912

Total operating expenses

(1,414,560 )

(402,766 )

Other income (expenses)

Interest expense, net

(56,740 )

(46,529 )

Change in fair value of warrant liability

164,000

Total other income (expenses), net

107,260

(46,529 )

Net loss

$ (1,307,300 )

(449,295 )

Less: net loss attributable to non-controlling interests

18,704

(7,515 )

Net loss attributable to Niki BioSolutions, Inc.

$ (1,326,004 )

$ (441,780 )

Revenue and cost

There was no revenue and cost

for both period due to reallocate resources towards the development of the Company’s leading projects.

Research and development expenses

comprised of costs incurred related to research and development activities, including payroll expenses to our research and development

staff, service fees to our consultants, advisory and contracted research organization, and amortization of licensed patents, sponsored

research programs with various universities and research institutions and costs in acquiring IP rights which did not meet the criteria

of capitalization under the U.S. GAAP. The following table sets forth a summary of our research and development expenses for the six months

ended June 30, 2026 and 2025. The increase in research and development expenses compared to the six months ended June 30, 2025 was primarily

attributable to expenses incurred in connection with the Management Services Agreement and Licensing Agreement entered into concurrently

with the Merger Agreement. Under the Management Services Agreement, DiamiR and Aptorum Therapeutics entered into arrangements for management

services, and under the Licensing Agreement, DiamiR and DiamiR, LLC licensed certain intellectual property to Aptorum Therapeutics on

a non-exclusive basis in exchange for upfront and periodic payments and royalties. These agreements terminated upon the closing of the

Merger. Accordingly, substantially all R&D expenses for the six months ended June 30, 2026 related to DiamiR, and other R&D activities

remained suspended as the Company focused its attention and resources on completing the Merger.

For the six months ended

June 30,

2026

2025

(Unaudited)

Research and Development Expenses:

DiamiR management services expenses

376,552

DiamiR licensing expenses

7,200

Other R&D expenses

19,375

Total Research and Development Expenses

383,752

19,375

For the six months ended

June 30,

2026

2025

(Unaudited)

R&D expenses by projects

ALS-4

$ -

$ 4,301

SACT-1

15,074

Other projects

383,752

Total

$ 383,752

$ 19,375

General and administrative fees

The following table sets forth

a summary of our general and administrative fees for the six months ended June 30, 2026 and 2025. General and administrative expenses

increased for the six months ended June 30, 2026 compared to the corresponding period in 2025, primarily due to management service fees

and other administrative costs incurred under the Management Services Agreement in connection with preparation for the Merger.

For the six months ended

June 30,

2026

2025

(Unaudited)

General and Administrative Fees:

Insurance

$ 81,376

$ 103,609

Rent and rates

88,236

63,016

Payroll expenses

19,057

Travelling expenses

1,740

DiamiR management services expenses

253,448

Other expenses

4,507

Total General and Administrative Fees

427,567

187,422

Legal and professional fees

For the six months ended June

30, 2026 and 2025, the legal and professional fees were $547,131 and $418,881, respectively. The increase in legal and professional fees

was primarily attributed to the non-routine activities such as potential merger activity that were present in the same period last year.

Such non-routine exercises in the current period have resulted in an increase in legal and professional fees.

Other operating (expenses) income

The other operating

expenses of $56,110 for the six months ended June 30, 2026 and the other operating income of $222,912 for the six months ended June

30, 2025 mainly represent the exchange gain arising on change in foreign exchange rate.

Other income (expenses)

The other income of $107,260 for the six months ended June 30, 2026 mainly represented the gain from change in fair value of warrant liability,

and the other expenses of $45,529 for the six months ended June 30, 2025 represented interest expense.

Net loss attributable to Niki BioSolutions,

Inc.

For the six months ended June

30, 2026 and 2025, net loss attributable to Niki BioSolutions, Inc. (excluding net loss attributable to non-controlling interests) was

$1,326,004 and $441,780, respectively.

LIQUIDITY AND CAPITAL RESOURCES

The Group reported a net

loss of $1,307,300, negative working capital of $2,475,418, and net operating cash outflow of $1,553,720 for the six months ended

June 30, 2026. In addition, the Group had an accumulated deficit of $75,118,802 as of June 30, 2026. The Group’s operating

results for future periods are subject to numerous uncertainties and it is uncertain if the Group will be able to reduce or

eliminate its net losses for the foreseeable future. If management is not able to generate significant revenues from its product

candidates currently in development, the Group may not be able to achieve profitability. Following the completion of the merger with

DiamiR in July 2026, management’s going concern assessment also considered DiamiR’s financial condition and cash flow

forecast as part of the Group’s liquidity analysis for the twelve months following the issuance of these unaudited condensed

consolidated financial statements. DiamiR has a limited operating history, has incurred recurring net losses and negative operating

cash flows, and its standalone financial statements indicate that its existing capital is not expected to be sufficient to fund its

operations for the next twelve months without additional financing. Successful transition to attaining profitable operations is

dependent upon achieving a level of revenues adequate to support the Company’s cost structure. In connection with the

Company’s assessment of going concern considerations in accordance with Financial Accounting Standard Board’s Accounting

Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a

Going Concern,” management has determined that these conditions raise substantial doubt about the Company’s ability to

continue as a going concern within one year after the date that these financial statements are issued.

If the Group is unable to

generate sufficient funds to finance the working capital requirements of the Group within the normal operating cycle of a twelve-month

period from the date of these financial statements are issued, the Group may have to consider supplementing its available sources of funds

through the following sources:

● other

available sources of financing from banks and other financial institutions or private lender; and

● equity

financing.

The Company can make no assurances

that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one

or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there

would likely be a material adverse effect on the Company and would materially adversely affect its ability to continue as a going concern.

The accompanying unaudited

condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly,

the unaudited condensed consolidated financial statements have been prepared on a basis that assumes the Group will continue as a going

concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.

CONTRACTUAL OBLIGATIONS

The following table sets forth

our contractual obligations as of June 30, 2026.

Payment Due by Period (Unaudited)

Total

less than

one year

One to

three years

Three to

five years

US$

Debt obligations

3,508,500

Total

3,508,500

Debt obligations

Debt obligations reflect outstanding

principal and accrued interest payable to Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to a convertible

note arrangement. This instrument features a conversion option at a price of $2.42 per share into the Company’s Class A Ordinary

Shares. It carries a two-year maturity from the date of issuance and bears an annual interest rate of 6%. On September 11, 2025 upon the

maturity of the convertible note, the Group entered into an extension agreement with Jurchen Investment Corporation to extend the convertible

note further for 12 months.

The Group can access up to

a total $12 million under a line of credit offered by Aeneas Group Limited. The line of credit was originally mature on August 12, 2022.

The Group and Aeneas Group Limited has mutually agreed to extend the line of credit arrangement further 3 years to August 12, 2026, and

the respective credit line have been extended further to August 2026. The interest on the outstanding principal indebtedness is at the

rate of 8% per annum. The Group may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time

prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty.

CONTINGENT PAYMENT OBLIGATIONS

As of June 30, 2026, we do

not have any non-cancellable purchase commitments.

The Group has contingency

payment obligations under each of the license agreements, such as milestone payments, royalties, research and development funding, if

certain condition or milestone is met.

Milestone payments are to

be made upon achievements of certain conditions, such as Investigational New Drugs (“IND”) filing or U.S. Food and Drug Administration

(“FDA”) approval, first commercial sale of the licensed products, or other achievements. The aggregate amount of the milestone

payments that we are required to pay up to different achievements of conditions and milestones for all the license agreements signed as

of June 30, 2026 are as below:

Amount

(unaudited)

Drug molecules: up to the conditions and milestones of

From entering phase 1 to before first commercial sale

$ 920,000

First commercial sale

800,000

Net sales amount more than certain threshold in a year

7,000,000

Subtotal

$ 8,720,000

For both the six months ended

June 30, 2026 and 2025, the Group incurred no milestone payments. For both the six months ended June 30, 2026 and 2025, the Group did

not incur any royalties or research and development funding.

CONDENSED SUMMARY OF OUR CASH FLOWS

Six months

ended

June 30,

2026

Six months

ended

June 30,

2025

(Unaudited)

Net cash used in operating activities

$ (1,553,720 )

$ (816,544 )

Net cash used in investing activities

(65,000 )

Net cash provided by financing activities

2,699,200

Net (decrease) increase in cash

$ (1,618,720 )

$ 1,882,656

For the six months ended June 30, 2026 and

2025

Operating activities

Net cash used in operating

activities amounted to $1.6 million and $0.8 million for the six months ended June 30, 2026 and 2025, respectively. The net cash used

in operating activities increased as a result of the Company’s exclusive emphasis on the previously anticipated Merger.

Investing activities

Net cash used in

investing activities amounted to $65,000 and nil for the six months ended June 30, 2026 and 2025, respectively, and no material

movement noted. The increase in net cash outflow from investing activities was associated with the loan to DiamiR.

Financing activities

Net cash provided by financing

activities amounted to nil and $2.7 million for the six months ended June 30, 2026 and 2025, respectively. The decrease in net cash inflow

from financing activities is attributed to the placing of shares in prior period.

Statement Regarding Unaudited Financial Information

The unaudited financial information

set forth above is subject to adjustments that may be identified when audit work is performed on the Company’s year-end financial

statements, which could result in significant differences from this unaudited financial information.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 21, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 21, 2026

Entity File Number

001-38764

Entity Registrant Name

Niki BioSolutions, Inc.

Entity Central Index Key

0001734005

Entity Tax Identification Number

42-3265309

Entity Incorporation, State or Country Code

Entity Address, Address Line One

116 Village Boulevard

Entity Address, Address Line Two

Suite 200

Entity Address, Address Line Three

17 Hanover Square

Entity Address, City or Town

Princeton

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

08540

City Area Code

609

Local Phone Number

951-2222

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.0001 per share

Trading Symbol

NIKI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Information, Former Legal or Registered Name

Aptorum Group Limited

[custom:EntityAddressCityOrTown2]

London

[custom:EntityAddressPostalZipCode2]

W1S 1BN

- References

No definition available.

+ Details

Name:

NIKI_EntityAddressCityOrTown2

Namespace Prefix:

NIKI_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- References

No definition available.

+ Details

Name:

NIKI_EntityAddressPostalZipCode2

Namespace Prefix:

NIKI_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

Former Legal or Registered Name of an entity

+ References

No definition available.

+ Details

Name:

dei_EntityInformationFormerLegalOrRegisteredName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration